Last reviewed · How we verify
NCT07232264
Respiratory and Peripheral Muscle Strength as Predictors of Inhaler Treatment Response in Asthma: A Comparison of DPI and MDI Devices
NA trial testing MDI Inhaler Therapy in Asthma (Diagnosis) in 80 participants. Completed in 24 September 2025.
24 September 2025
Quick facts
| Lead sponsor | Bugra Kerget |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 March 2025 |
| Primary completion | 24 September 2025 |
| Estimated completion | 24 September 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- MDI Inhaler Therapy — full drug profile →
- DPI Inhaler Therapy — full drug profile →
Conditions studied
- Asthma (Diagnosis) — all drugs for Asthma (Diagnosis) →
Sponsor
Bugra Kerget — full company profile →
Who can join
18 and older, any sex, with Asthma (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Asthma is a chronic respiratory disease characterized by variable airway obstruction. Inhaled therapies are the cornerstone of asthma management, and selecting the appropriate inhaler device is essential for effective treatment. Among available devices, metered dose inhalers (MDIs) and dry powder inhalers (DPIs) are commonly used; however, their effectiveness depends not only on the medication but also on the patient's physiological capacity and inhalation technique. This prospective randomized study aimed to evaluate the factors influencing inhaler treatment response in newly diagnosed asthma patients. A total of 80 patients with at least a high school education, who demonstrated perfect inhaler technique and adherence, were randomly assigned to MDI or DPI groups (n = 40 each). Baseline and one-month follow-up assessments included pulmonary function tests (PFTs), inspiratory and expiratory muscle strength measurements (MIP, MEP), Asthma Control Test (ACT), and handgrip strength (HGS). The study investigated how respiratory and peripheral muscle strength, inspiratory capacity, coordination skills, and clinical status affect treatment outcomes with MDI and DPI. Findings from this research may help guide inhaler selection based on patient-specific physiological characteristics to optimize treatment effectiveness.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07232264
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Asthma (Diagnosis)
Currently open trials in the same condition.
- NCT07507682 — Can Astaxanthin Help Manage Asthma in POlluted Areas? · NA · recruiting
- NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
- NCT07529847 — Comparative Effects of Alternative Nostril Breathing Versus Buteyko Breathing on Control Pause, Dyspnea and Pulmonary Fu · NA · recruiting
- NCT07356310 — Body Composition Related Evaluation of Airway Tone and Hyper-rEactivity Using Oscillometry · recruiting
- NCT07301060 — Optimizing a Sensor-Enabled mHealth Intervention for Adolescents With Suboptimal Asthma Control · NA · recruiting
Other Bugra Kerget trials
Trials by the same sponsor.
- NCT07001462 — Effectiveness of IMT/PEP Therapy in Group E COPD and Comparison of GOLD vs STAR Classifications · completed
- NCT05094596 — Effect of Montelukast Therapy on Clinical Course, Pulmonary Function, and Mortality in Patients With COVID-19 · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07232264 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bugra Kerget
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07232264.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing